Managing chronic subdural hematoma presents a persistent clinical challenge for neurosurgeons, neurologists, and physicians worldwide. Clinicians frequently encounter older individuals who require concurrent antithrombotic agents for underlying cardiovascular and cerebrovascular conditions. However, stopping antiplatelets increases ischemic vascular events, while restarting them prematurely might induce recurrent intracranial hemorrhage. Consequently, neurosurgeons have explored middle meningeal artery embolization as a therapeutic adjunct to standard surgical drainage. Emerging data suggest that devascularizing the hypervascular neomembranes stabilizes the subdural collection. Therefore, this endovascular intervention may widen the therapeutic window for timely antithrombotic resumption.

The Rationale for Middle Meningeal Artery Embolization

Chronic subdural hematoma involves chronic inflammation, fragile angiogenic capillary networks, and recurrent microbleeding along the outer neomembrane. Traditional burr-hole craniostomy rapidly evacuates the fluid collection, but it does not eradicate the driving vascular pathology. Consequently, hematoma recurrence rates historically reach ten to twenty percent. When patients require secondary antiplatelet therapy for coronary stents or ischemic stroke, recurrence risks climb even higher. Middle meningeal artery embolization addresses this vulnerability by occluding distal dural feeding branches. In addition, endovascular microcatheters deliver liquid embolic agents or particles directly into the arterial network. As a result, the embolization stops active fluid exudation and halts repetitive microhemorrhages. Furthermore, interventional teams perform the procedure either as standalone therapy for stable collections or as an operative adjunct during initial surgical evacuation. Moreover, this minimally invasive approach can significantly shorten inpatient recovery and reduce hospital readmission rates. In clinical settings across India and globally, this combination targets both mechanical decompression and biological stabilization. Ultimately, sealing these abnormal fragile vessels provides a robust safeguard against postoperative rebleeding. Therefore, endovascular embolization has emerged as a promising paradigm shift in neurovascular care.

Study Design and Propensity-Matched Cohort Analysis

To clarify this dilemma, investigators analyzed real-world records from the TriNetX research network between May 2020 and May 2025. Specifically, they identified adult chronic subdural hematoma patients using validated diagnostic and pharmacological coding systems. Furthermore, the researchers constructed two distinct propensity score-matched cohorts to control for confounding baseline comorbidities. The first analysis evaluated surgical evacuation with adjunct embolization, stratifying patients by antiplatelet restart within thirty days. In this matched subset, researchers balanced 163 patients per arm for cardiovascular risk factors and demographics. Meanwhile, the second analysis compared antiplatelet-treated patients receiving surgery with embolization against surgery alone, balancing 176 patients per group. Primary outcome metrics focused on rescue surgical interventions and all-cause six-month mortality rates. In addition, propensity score matching effectively minimized selection bias between the treatment arms. Consequently, these matched comparisons provide valuable real-world evidence regarding clinical safety and patient outcomes in complex neurovascular populations.

Safety of Early Antiplatelet Reinitiation

For decades, neurosurgeons hesitated to restart antiplatelet agents early because they feared fatal rebleeding. However, the findings from this multicenter study provide considerable reassurance. Among patients receiving surgical evacuation with adjunctive middle meningeal artery embolization, resuming antiplatelet therapy within thirty days did not increase rescue surgery rates. Specifically, the odds ratio for rescue intervention was 0.68 with a confidence interval spanning 0.32 to 1.48. In addition, early antiplatelet reinitiation did not significantly elevate six-month mortality, showing an odds ratio of 1.52. These figures demonstrate that early platelet inhibition does not compromise surgical hemostasis when endovascular devascularization occludes neomembrane feeders. Furthermore, avoiding prolonged antithrombotic interruption protects high-risk vascular patients against stent thrombosis, myocardial infarction, and recurrent ischemic stroke. Clinicians often observe catastrophic thromboembolic events when withholding antiplatelets for more than four weeks. Therefore, early resumption under the vascular protection of arterial embolization resolves a major clinical dilemma. Consequently, surgical teams can formulate structured antithrombotic protocols with enhanced confidence.

Mortality Reduction and Comparative Clinical Outcomes

The comparative analysis between antiplatelet-treated cohorts yielded especially striking observations. Patients undergoing surgical drainage alone experienced a six-month mortality rate of 21.0 percent. In contrast, patients receiving surgical evacuation with adjunctive middle meningeal artery embolization demonstrated a six-month mortality of only 10.8 percent. Statistically, this reduction represents an odds ratio of 0.46 with a p-value of 0.009. Rescue surgery rates remained statistically equivalent between the two cohorts. Nonetheless, the substantial halving of mortality underscores potential systemic advantages of combined therapy. Notably, maintaining secondary cardiovascular prevention without provoking recurrent subdural expansion likely explains part of this survival advantage. In addition, avoiding repeated hospitalizations and secondary hematoma expansions mitigates systemic complications such as sepsis, immobilization, and deep venous thrombosis. Although observational findings require cautious interpretation, these survival differences indicate meaningful real-world benefits. Therefore, combining endovascular devascularization with surgical drainage offers measurable advantages beyond simple local hematoma control. Accordingly, interventional teams should consider this strategy for high-risk elderly populations.

Translating Evidence into Clinical Practice in India

The burden of chronic subdural hematoma is rising rapidly across India due to expanding life expectancy. Moreover, widespread cardiovascular disease and percutaneous coronary interventions mean that many elderly Indian patients take lifelong antiplatelet drugs. In traditional practice, clinicians frequently withhold aspirin or clopidogrel for several weeks following burr-hole evacuation. Unfortunately, this prolonged hiatus creates severe vulnerability to acute coronary syndromes and ischemic strokes. By adopting adjunctive middle meningeal artery embolization, tertiary neurosurgical centers can offer safer management pathways. Furthermore, neurointerventional facilities in major Indian metropolitan hospitals already possess the requisite endovascular tools and catheter technology. Multidisciplinary collaboration between neurosurgeons, interventional radiologists, and cardiologists remains essential for optimal patient selection. Furthermore, adopting standardized multidisciplinary pathways ensures timely therapeutic anticoagulation and antiplatelet management across tertiary care centers. Consequently, institutional protocols should clearly delineate safe timelines for resuming dual or single antiplatelet regimens. In addition, hospitals must balance cost considerations against the heavy expenses associated with recurrent operations and prolonged intensive care. Ultimately, proactive embolization can reduce overall healthcare expenditure by preventing secondary neurosurgical salvage procedures.

Critical Limitations and Future Research Directions

While these retrospective findings provide encouraging evidence, clinicians must consider several methodological limitations. First, the TriNetX database relies on electronic health record coding, which lacks granular neuroimaging dimensions. For instance, the dataset cannot capture midline shift, hematoma volume, or trabecular internal architecture. Second, retrospective matching cannot fully eliminate unmeasured physician bias regarding surgical candidacy. In addition, researchers could not distinguish between specific antiplatelet agents, such as aspirin versus P2Y12 inhibitors. Therefore, the observed reduction in mortality remains hypothesis-generating rather than definitive proof of causality. Prospective randomized controlled trials must validate whether adjunctive middle meningeal artery embolization directly lowers mortality in antithrombotic users. Meanwhile, ongoing randomized trials worldwide will establish precise drug resumption windows. Until then, clinicians should individualize decisions based on each patient's thrombotic risk and hematoma characteristics. Consequently, cautious multidisciplinary evaluation remains the gold standard in neurosurgical practice.

How does middle meningeal artery embolization prevent subdural hematoma recurrence?

The procedure occludes distal branches of the middle meningeal artery that supply the outer neomembrane of the hematoma. By blocking abnormal angiogenic microvessels, embolization halts recurrent microhemorrhages and fluid exudation. Consequently, this endovascular devascularization stabilizes the subdural collection and allows the brain to re-expand without ongoing inflammation.

When can clinicians safely restart antiplatelet therapy after surgical evacuation and embolization?

Recent clinical data indicate that resuming antiplatelet therapy within thirty days after combined surgery and embolization is safe. The intervention does not increase rescue surgery rates or mortality. Nevertheless, clinicians should verify post-procedure neurological stability and obtain repeat intracranial imaging before restarting antiplatelet medications in high-risk patients.

Why is adjunctive embolization linked to lower six-month mortality in antiplatelet users?

Adjunctive embolization likely reduces mortality by allowing safer, uninterrupted antithrombotic management for critical cardiovascular comorbidities. Furthermore, preventing hematoma recurrence averts secondary surgical procedures, prolonged hospitalization, and associated complications like immobilization, sepsis, and venous thromboembolism. These combined protective effects significantly improve overall survival in vulnerable elderly populations.

Disclaimer: This content is for informational and educational purposes only and should not be taken as professional medical advice. Always seek the advice of a qualified healthcare provider regarding medical conditions or treatment decisions. Refer to the latest local and national guidelines for clinical practice.

References

1. Essibayi MA et al. Reinitiating antiplatelet therapy in chronic subdural hematoma: Does adjunctive middle meningeal artery embolization improve outcomes? Neurosurg Rev. 2026 May 09. doi: 10.1007/s10143-026-04318-6. PMID: 42103984.
2. Kasem RA, Venegas JM, Ibrahim A, et al. Can antithrombotic therapy be safely resumed after middle meningeal artery embolization with or without surgery for chronic subdural hematoma? a systematic review and meta-analysis. Acta Neurochir (Wien). 2025;167(1):183.
3. Alhazzani AA, et al. Antithrombotic resumption after middle meningeal artery embolization or surgery for chronic subdural hematoma: a systematic review and meta-analysis. J Neurointerv Surg. 2026. doi: 10.1136/jnis-2024-022988.